Molecular Insight buys Texas radiopharma plant

AuntMinnie.com staff writers
May 17, 2007

Molecular Insight Pharmaceuticals of Cambridge, MA, said it plans to buy a radiopharmaceutical manufacturing facility in Texas for $3 million.

The company is buying the facility, located in Denton, from NeoRx Manufacturing Group, a wholly owned subsidiary of Poniard Pharmaceuticals of South San Francisco, CA. Molecular Insight said the deal is in line with its strategy to buy a radiopharmaceutical manufacturing facility for the production of its molecular imaging products Zemiva and Trofex, and its targeted radiotherapeutic products like Azedra, Onalta, and Solazed.

By AuntMinnie.com staff writers
May 18, 2007

Related Reading

Molecular Insight adds revenues in Q1, May 15, 2007

Molecular Insight prices IPO, February 2, 2007

Molecular Insight starts phase I neuroendocrine cancer trial, June 22, 2006

Molecular Insight begins phase II clinical trial, March 27, 2006

MDS Nordion, Molecular Insight Pharmaceutical partner, February 16, 2006

Copyright © 2007 AuntMinnie.com

Latest in Molecular Imaging
Individualized parametric z-score maps of the brain showing glial activity load in the brain, compared among individuals with secondary progressive MS (SPMS) (top row), relapsing-remitting MS (RRMS) (middle row), and a healthy control (HC) (bottom row) in transaxial, sagittal, and coronal sections. Image courtesy of Clinical Nuclear Medicine.
PET reveals ‘smoldering’ brain inflammation in patients treated for MS
April 29, 2024
Driving the future of PET/CT.
Sponsored
Driving the future of PET/CT.
April 17, 2024
Examples in two patients. (Top) Abnormal leukocyte accumulation was observed in the right 1st to 5th toes, with the radioactive lesions extending to the bone, indicating osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). Two spherical VOIs were drawn on diabetic foot infections (DFIs) and the highest SUVmax was 4.2 (higher than the cutoff of 1.1) Despite intensive treatment, the infection progressed, leading to the patient undergoing right below knee amputation 43 days after SPECT/CT. (Bottom) Mild focal abnormal leukocyte accumulation was detected in the right 3rd and 4th toes. The lesions were in contact with the bone, which raised a suspicion of osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). A circular VOI was drawn on DFIs and the SUVmax was 1.0 (lower than the cutoff of 1.1). After 10 weeks of antibiotic treatment, the infection was successfully resolved, and the foot was preserved. Image and caption courtesy of Scientific Reports.
SPECT/CT predicts foot amputations in diabetics
April 24, 2024
Ppgl 167 250
PET/CT superior to MRI for detecting spinal bone metastases
April 23, 2024
Related Stories
2007 04 25 15 03 31 706
Nuclear Medicine
PET plays universal role in pre- and post-treatment for head and neck cancer
2007 03 29 14 59 45 706
Nuclear Medicine
Rubidium PET/CT shows potential for coronary artery disease diagnosis
2007 03 22 15 08 30 706
Nuclear Medicine
SPECT/CT offers on-target diagnosis in noncancerous bone disease
Driving the future of PET/CT.
Sponsor Content
Driving the future of PET/CT.
More in Molecular Imaging
PET reveals ‘smoldering’ brain inflammation in patients treated for MS
By Will Morton
PET brain scans show persistent brain inflammation in patients with multiple sclerosis (MS), despite being treated with therapies.
April 29, 2024
Individualized parametric z-score maps of the brain showing glial activity load in the brain, compared among individuals with secondary progressive MS (SPMS) (top row), relapsing-remitting MS (RRMS) (middle row), and a healthy control (HC) (bottom row) in transaxial, sagittal, and coronal sections. Image courtesy of Clinical Nuclear Medicine.
Dual-tracer PET/CT shows promise in liver cancer patients
By Will Morton
Dual-tracer PET/CT appears valuable for improving tumor staging in patients with hepatocellular carcinoma being evaluated for treatment.
April 26, 2024
Liver Cancer
SPECT/CT predicts foot amputations in diabetics
By Will Morton
Technetium-99m white blood cell SPECT/CT imaging may be useful for identifying diabetic patients at risk of amputations due to foot infections.
April 24, 2024
Examples in two patients. (Top) Abnormal leukocyte accumulation was observed in the right 1st to 5th toes, with the radioactive lesions extending to the bone, indicating osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). Two spherical VOIs were drawn on diabetic foot infections (DFIs) and the highest SUVmax was 4.2 (higher than the cutoff of 1.1) Despite intensive treatment, the infection progressed, leading to the patient undergoing right below knee amputation 43 days after SPECT/CT. (Bottom) Mild focal abnormal leukocyte accumulation was detected in the right 3rd and 4th toes. The lesions were in contact with the bone, which raised a suspicion of osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). A circular VOI was drawn on DFIs and the SUVmax was 1.0 (lower than the cutoff of 1.1). After 10 weeks of antibiotic treatment, the infection was successfully resolved, and the foot was preserved. Image and caption courtesy of Scientific Reports.
PET/CT superior to MRI for detecting spinal bone metastases
By Will Morton
Gallium-68 DOTATATE PET/CT appears to be the best approach for detecting spinal bone metastases in patients with certain neuroendocrine tumors.
April 23, 2024
Ppgl 167 250
Neuroimaging detects blast exposure brain injuries in U.S. soldiers
By Will Morton
A battery of MRI and PET neuroimaging tests show patterns of brain injury in active-duty U.S. soldiers caused by repeated blast exposures.
April 22, 2024
Military
PET/MRI reveals sex differences in patients with autism
By Will Morton
PET/MRI shows that young women with autism spectrum disorder have increased brain metabolism associated with translocator protein.
April 18, 2024
Tspo Thumbnail
PET tracer for gliomas under expedited review
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Telix Pharmaceuticals’ PET radiotracer F-18 floretyrosine (Pixclara) for imaging progressive or recurring gliomas.
April 17, 2024
Gliomas
FAPI-PET shows promise in patients with lung cancer
By Will Morton
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans.
April 15, 2024
F-18 FDG and Ga-68 FAPI-46 images of a 51-year-old woman with adenocarcinoma with lepidic growth pattern in right upper lobe. (A) Maximum-intensity-projection PET images. The lesion had F-18 FDG uptake below blood pool level but was strongly Ga-68 FAPI-46-positive. CT-guided biopsy led to pathologic diagnosis of adenocarcinoma, and the patient was treated by stereotactic body radiation therapy because of functional inoperability. Image courtesy of the Journal of Nuclear Medicine.
Vision transformer AI model boosts PET/CT imaging of cancer
By Will Morton
A vision transformer AI model outperformed convolutional neural networks when classifying tumors on PET/CT images as benign or malignant.
April 12, 2024
Predictions and Grad-CAMs of ViT-based models on sample PET/CT, PET, and CT test images from the “positive” class. ViT was fine-tuned using training data for each modality. The bounding boxes depicted in the figure indicate malignant lesions. The top row of the Grad-CAMs shows important areas for “positive” predictions, and the bottom row shows areas for “negative” predictions. Image courtesy of Scientific Reports.
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.
April 9, 2024
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
PET/MRI detects brain injury in pediatric cancer survivors
By Will Morton
PET/MRI could be a tool for diagnosing brain injury due to high-dose methotrexate treatment in young cancer survivors.
April 8, 2024
A visual abstract of the study. Image courtesy of the Journal of Nuclear Medicine.
Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio
By AuntMinnie.com staff writers
Life Molecular Imaging and Sofie Biosciences have begun offering the Neuraceq PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio.
April 5, 2024
Brain Puzzle Dementia Social
Page 1 of 593
Next Page